Physicochemical and biological comparison of the first Brazilian biosimilar filgrastim with its reference product

References

• Gravel P, Naik A, Le Cotonnec J-Y. Biosimlar rhG-CSFs: how similar are they? Target Oncol. 2012;7(suppl 1):S3–S16.
   PubMedGoogle Scholar
• Federici M, Lubiniecki A, Manikwar P, Volkin DB. Analytical lessons learned from selected therapeutic protein drug comparability studies. Biologicals. 2013;41(3):131–147.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guidelines on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues. London: European Medicines Agency; 2014.
   Google Scholar
• European Medicines Agency. Guidelines on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. London: European Medicines Agency; 2013.
   Google Scholar
• Kelly C, Mir F. Economics of biological therapies. BMJ. 2009;339:b3276.
   PubMed Web of Science ®Google Scholar
• European Directorate for the Quality of Medicines. Filgrastim concentrated solution (2206). Eur Pharmacopeia. 2009;6(3):4142–4144.
   Google Scholar
• Agência de Vigilância Sanitária [webpage on the Internet]. Guia para validação de métodos analíticos e bioanalíticos. RE nº 899 published in May 29, Brasília, 2003. Available from: http://portal.anvisa.gov.br/wps/wcm/connect/4983b0004745975da005f43fbc4c6735/RE_899_2003_Determina+a+publica%C3%A7%C3%A3o+do+Guia+para+valida%C3%A7%C3%A3o+de+m%C3%A9todos+anal%C3%ADticos+e+bioanal%C3%ADticos.pdf?MOD=AJPERES. Accessed May 4, 2016.
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [webpage on the Internet]. Validation of Analytical Procedures: Text and Methodology – Q2(R1). Parent guideline published in October 27, 1994, revised in 2005. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf. Accessed May 4, 2016.
   Google Scholar
• Sreerama N, Woody RW. Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with and expanded reference set. Anal Biochem. 2000;287(2):252–260.
   PubMed Web of Science ®Google Scholar
• Sreerama N, Venyaminov SY, Woody RW. Analysis of protein circular dichroism spectra based on the tertiary structure classification. Anal Biochem. 2001;299(2):271–274.
   PubMed Web of Science ®Google Scholar
• Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Crystallogr. 1993;26(6):795–800.
   Google Scholar
• Adams PD, Grosse-Kunstleve RW, Hung L-W, et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr. 2002;58(Pt 11):1948–1954.
   Google Scholar
• Agência de Vigilância Sanitária. Guia para Realização do Exercício de Comparabilidade para Registro de Produtos Biológicos. Brasilia: Agência de Vigilância Sanitária; 2011.
   Google Scholar
• US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Rockville, MD: US Food and Drug Administration; 2015.
   Google Scholar
• Hill CP, Osslundt TD, Eisenberg D. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc Natl Acad Sci USA. 1993;90(11):5167–5171.
   Web of Science ®Google Scholar
• Greenfield NJ. Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions. Nat Protoc. 2006;1(6):2527–2535.
   PubMed Web of Science ®Google Scholar
• Ladoklhin AS. . Fluorescence spectroscopy in peptide and protein analysis. In: Meyers RA, editor. Encyclopedia of Analytical Chemistry. Chichester: John Wiley & Sons Ltd; 2000:5762–5779.
   Google Scholar
• Sörgel F, Lerch H, Lauber T. Physicochemical and biological comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs. 2010;24(6):347–357.
   Web of Science ®Google Scholar
• Berghout A. Clinical programs in the development of similar biotherapeutic products: rationale and general principles. Biologicals. 2011;39(5):293–296.
   Web of Science ®Google Scholar
• Skrlin A, Radic I, Vuletic M, et al. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals. 2010;38(5):557–566.
   PubMed Web of Science ®Google Scholar